What is amyloid cardiomyopathy?

Cardiac amyloidosis is a rare infiltrative cardiomyopathy caused by the deposition of abnormally folded amyloid proteins in the myocardium, leading to myocardial stiffening and impaired systolic and diastolic function. The disease progresses slowly and insidiously; in advanced stages, it commonly triggers heart failure and arrhythmias. Unexplained fatigue, chest tightness, or edema warrant prompt medical evaluation for diagnosis.

The core pathological feature involves progressive accumulation of abnormal proteins within the myocardial interstitium, gradually replacing normal myocardial tissue. This results in ventricular wall rigidity and reduced ventricular compliance, impairing normal cardiac filling and pumping. Clinically, patients commonly present with exertional dyspnea, lower-limb edema, and palpitations. Treatment must be tailored to the specific subtype: targeted therapies suppress abnormal protein production, while heart-failure medications improve cardiac function and slow disease progression.

Cardiac amyloidosis is primarily classified into light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis—some subtypes are associated with genetic mutations or hematologic disorders. Early symptoms are often nonspecific and easily misdiagnosed as common heart failure; untreated, the disease causes ongoing structural damage to the myocardium. In advanced stages, severe heart failure and life-threatening arrhythmias may develop, resulting in relatively poor prognosis. Timely, standardized treatment significantly reduces the risk of disease deterioration and helps preserve baseline cardiac function.

In daily life, strict control of dietary sodium and fluid intake is essential; strenuous exercise should be avoided to prevent excessive cardiac strain. Maintaining stable emotional well-being and regular sleep patterns, along with routine monitoring of physical status, supports long-term stability of cardiac function.